Novel approach treats C. difficile hospital infections

Calgary, AB – Using data collected at the Canadian Light Source, researchers have revealed the first molecular views showing how antibodies derived from llamas may provide a new method for controlling the highly infectious disease C. difficile, common in healthcare facilities.

One of the most problematic hospital-acquired infections worldwide, C. difficile (Clostridium difficile) is an opportunistic bacterial pathogen that causes extreme diarrhea and potentially fatal colon inflammation. This new research provides exciting opportunities for creating a new generation of engineered antibodies that will be more effective at preventing the toxins from damaging the intestine during the normal course of the disease.

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have shown for the first time how antibodies recognize the disease’s two central toxin proteins: toxin A (TcdA) and toxin B (TcdB). The research was published in the Journal of Biological Chemistry.

“Our research is an important step towards developing highly specific ways to treat this very common and serious disease,” says Kenneth Ng, associate professor in the Department of Biological Sciences at the University of Calgary and the study’s senior author.

The key findings in the paper derive from the three-dimensional structures of antibody-toxin complexes that were determined using X-ray crystallography by Tomohiko Murase, Luiz Eugenio and Melissa Schorr in Ng’s laboratory. The antibody-toxin complexes were developed using single-domain antibodies derived from llamas.

“The smaller size of the llama antibodies compared to the monoclonal antibodies currently used for diagnostics or in development for therapeutics greatly assists with structure determination and protein engineering,” explains Ng. “Starting from these structures, we are now creating modified antibodies for improving treatments in the future.”

“Basic biological research on llamas, camels and sharks led to the discovery of a smaller type of antibody with a simpler structure,” adds Ng. “It is this simpler structure that allows us to make modifications and perform many detailed studies that are not easily done with other types of antibodies. The unique characteristics of these single-domain antibodies provide an attractive approach for developing new treatments for C. difficile.”

According to Ng, although the research is at the fundamental science level, the new structures provide a blueprint for designing new molecules that could neutralize the bacterial toxins more effectively than anything currently available.

This project relied on important contributions from Elena Kitova in John Klassen’s mass spectrometry group at the Alberta Glycomics Centre, at the University of Alberta, as well as from Greg Hussack in Jamshid Tanha’s antibody therapeutics group at the National Research Council in Ottawa.

The research was primarily supported by the Alberta Glycomics Centre, which is funded by Alberta Innovates Technology Futures, as well as the Natural Sciences and Engineering Research Council of Canada, and the National Research Council of Canada.  Crystallographic work was performed at the CLS synchrotron in Saskatoon and the Stanford Synchrotron Radiation Light Source in California.